Medicare’s relationship with GLP-1 drugs is the single most important coverage question in US healthcare policy. Roughly 67 million Americans get coverage through Medicare, including more than 40% of US adults over 65, and about 42% of that population is classified as obese under BMI criteria. A full obesity benefit could add $25 billion to $35 billion in annual Medicare drug spending.<\/p>\n
The short answer for 2026: Medicare Part D still cannot cover GLP-1s prescribed for weight loss alone, because of a statutory exclusion in the Medicare Modernization Act of 2003. But cardiovascular, diabetes, sleep apnea, and kidney disease labels have created multiple back-door coverage pathways that now reach a meaningful fraction of obese Medicare beneficiaries.<\/p>\n
At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.<\/p>\n
The Medicare Modernization Act of 2003, which created the Part D prescription drug benefit, included an explicit list of drug categories that Part D plans cannot cover.<\/strong> Section 1860D-2(e)(2) of the Social Security Act bars coverage for “agents when used for anorexia, weight loss, or weight gain.” That language was written when older weight loss drugs like fenfluramine and sibutramine had safety problems, and Congress did not want Medicare paying for them.<\/p>\n Quick Answer: Medicare Part D is statutorily prohibited from covering drugs used for “weight loss” under 42 U.S.C. \u00a7 1395w-102(e)(2)<\/p>\n The exclusion applies to the indication, not the drug itself. A Medicare beneficiary prescribed Wegovy\u00ae or Zepbound\u00ae purely for obesity treatment cannot use Part D to pay for it. The same beneficiary prescribed Wegovy for cardiovascular risk reduction in obesity (the indication FDA approved in March 2024) can get Part D coverage.<\/p>\n Repealing or amending that exclusion requires an act of Congress. The Treat and Reduce Obesity Act (TROA) has been introduced in every Congress since 2012 and never received a floor vote in either chamber.<\/p>\n Novo Nordisk submitted data from the SELECT trial (Lincoff et al.<\/strong> 2023 NEJM) showing semaglutide cut major adverse cardiovascular events by 20% in adults with overweight or obesity and existing cardiovascular disease. The FDA added cardiovascular risk reduction to the Wegovy label in March 2024.<\/p>\n The Centers for Medicare and Medicaid Services issued a memo (HPMS Memo, March 21, 2024) clarifying that Part D plans could cover Wegovy when prescribed for the cardiovascular indication, because cardiovascular risk reduction is not “weight loss.” This was the first major break in the Medicare exclusion since 2003.<\/p>\n By the end of 2024, more than 80% of Part D plans had added Wegovy to their formularies for the cardiovascular indication, typically with prior authorization requiring documented cardiovascular disease and either BMI 27 with comorbidities or BMI 30. KFF estimated this pathway reached about 7% of Medicare beneficiaries.<\/p>\n Eli Lilly took a similar route with the SURMOUNT-OSA trials showing tirzepatide improved obstructive sleep apnea metrics in adults with obesity.<\/strong> The FDA approved Zepbound for moderate to severe OSA in adults with obesity in December 2024, making it the first drug approved for sleep apnea.<\/p>\n CMS issued guidance in early 2025 allowing Part D coverage of Zepbound for the OSA indication. Estimates suggest roughly 6 to 10 million Medicare beneficiaries have undiagnosed or diagnosed OSA with obesity, opening a second back-door coverage pathway.<\/p>\n Insurance coverage in 2026 typically requires polysomnography confirming AHI of 15 or higher, BMI of 30 or higher, and documentation of the OSA diagnosis. Some plans also require prior trials of CPAP therapy.<\/p>\n Yes, for type 2 diabetes.<\/strong> Both Ozempic (semaglutide) and Mounjaro (tirzepatide) are approved for type 2 diabetes mellitus, and that indication has been covered under Part D since each product launched. Roughly 11 million Medicare beneficiaries have type 2 diabetes, and a meaningful fraction now use GLP-1 therapy.<\/p>\n A January 2024 KFF analysis found Medicare spent $5.7 billion on Ozempic in 2022, making it Medicare’s second-largest drug by gross spending. Trulicity\u00ae and Mounjaro added several billion more. These figures predate the cardiovascular and OSA coverage expansions.<\/p>\n Beneficiaries who have diabetes plus obesity often access GLP-1 therapy through the diabetes label even when their primary clinical goal is weight loss. This pattern is common and not technically a regulatory problem because the diabetes indication is FDA-approved.<\/p>\n The FLOW trial (Perkovic et al.<\/strong> 2024 NEJM) showed semaglutide cut kidney failure progression or cardiovascular death by 24% in adults with type 2 diabetes and chronic kidney disease. The trial was stopped early for efficacy in October 2023.<\/p>\n Novo Nordisk filed for an FDA label expansion in 2024 and approval is expected in 2026. Once approved, the CKD indication would not face the weight loss exclusion under Part D, since these patients already have diabetes (which is covered) and the new label simply adds renal protection as an outcome.<\/p>\n The clinical population is large. About 4 million Medicare beneficiaries have type 2 diabetes with CKD. The FLOW data, combined with the existing diabetes label, will likely become a primary driver of GLP-1 prescribing in this group.<\/p>\n TROA is the proposed federal legislation that would explicitly authorize Medicare Part D to cover anti-obesity medications and intensive behavioral therapy for obesity.<\/strong> The bill has been introduced in every Congress since 2012.<\/p>\n The 2023-2024 version was introduced as S. 2407 in the Senate by Tom Carper (D-DE) and Bill Cassidy (R-LA) and as H.R. 4818 in the House by Brad Wenstrup (R-OH) and Raul Ruiz (D-CA). It had bipartisan support but never received a markup or floor vote, primarily because of CBO scoring concerns about cost.<\/p>\n The Congressional Budget Office scored a 2024 version at $35 billion over 10 years, which CBO indicated would be partially offset by reduced spending on obesity-related complications. The net cost remained significant enough to block movement under reconciliation budget rules.<\/p>\n A November 2024 Biden administration proposal would have used regulatory authority to reinterpret the existing exclusion and cover anti-obesity medications, but the proposal was withdrawn in early 2025 by the incoming administration.<\/p>\n Key Takeaway: The Treat and Reduce Obesity Act (TROA) has been introduced in every Congress since 2012 without passage<\/p>\n Medicaid is separate from Medicare and has different rules.<\/strong> Each state’s Medicaid program decides whether to cover anti-obesity medications. As of early 2026, about 16 state Medicaid programs cover Wegovy or Zepbound for obesity, including California, New York, Pennsylvania, and Massachusetts. The remaining states either restrict coverage to specific comorbidities or do not cover anti-obesity drugs at all.<\/p>\n State Medicaid programs all cover semaglutide and tirzepatide when prescribed for diabetes under federal Medicaid drug rebate program rules. The split mirrors the Medicare pattern: diabetes indication universally covered, obesity indication variable.<\/p>\n The Department of Veterans Affairs covers Wegovy and Zepbound for veterans meeting clinical criteria, typically BMI of 30 or BMI of 27 with comorbidities.<\/strong> The VA negotiates substantially lower prices than Medicare under the Federal Supply Schedule.<\/p>\n TRICARE, which covers active-duty military and dependents, covers Wegovy and Zepbound for the OSA and cardiovascular indications but generally not for obesity alone. Coverage decisions are made by the Defense Health Agency and updated periodically.<\/p>\n Three pathways could expand Medicare coverage in 2026 and beyond:<\/p>\n Regulatory reinterpretation. CMS could revise its interpretation of the weight loss exclusion to permit coverage when GLP-1s are prescribed for documented obesity-related comorbidities. The Biden administration proposed something along these lines in November 2024 before withdrawing it. The current administration has not signaled support.<\/p>\n Legislative action. TROA would need to pass Congress, which would require either bipartisan support strong enough to overcome budget concerns or inclusion in a larger legislative vehicle. Patient advocacy groups including the Obesity Action Coalition continue to lobby for passage.<\/p>\n Label expansions. Each new FDA approval (MASH, additional cardiovascular populations, kidney disease) opens additional Medicare coverage pathways that work around the exclusion. The pipeline supports continued back-door expansion through 2028.<\/p>\n The practical effect of these pathways is significant. By late 2025, an estimated 4 to 6 million Medicare beneficiaries had access to GLP-1 therapy through some covered indication, up from essentially zero in 2022.<\/p>\n Even with Part D coverage, Medicare beneficiaries face out-of-pocket costs.<\/strong> For 2025, the Inflation Reduction Act capped Part D out-of-pocket spending at $2,000 per year. That cap applies once a beneficiary reaches the catastrophic phase of coverage.<\/p>\n For Wegovy or Zepbound at list prices over $12,000 annually, most covered beneficiaries reach the $2,000 cap quickly. After that, the plan covers the remaining cost. Coverage gaps and tiering still apply during the initial deductible and coverage phases.<\/p>\n Beneficiaries without coverage for an indication face the full cash price, which for Wegovy and Zepbound runs $1,000 to $1,400 per month. Both manufacturers introduced direct-to-consumer programs in 2024-2025 with cash prices around $349 to $499 monthly, available without insurance.<\/p>\n Medicare beneficiaries who don’t qualify for a covered indication have a few options:<\/p>\n Manufacturer direct pricing. LillyDirect ($349-499\/month for Zepbound) and Wegovy direct ($499\/month) offer cash pricing well below the list price. Patients pay out of pocket without using insurance.<\/p>\n Pharmaceutical assistance programs. Both Novo Nordisk and Eli Lilly run patient assistance programs for low-income patients, with eligibility typically capped at 400% of federal poverty level.<\/p>\n Compounded GLP-1 telehealth. Personalized compounded semaglutide and tirzepatide through telehealth platforms remains available under section 503A of the Federal Food, Drug, and Cosmetic Act. Pricing typically runs $150 to $400 per month. TrimRx offers a free assessment quiz to determine eligibility.<\/p>\n State Medicaid expansion. Some states expanded Medicaid coverage of anti-obesity medications in 2024 and 2025, and additional state coverage decisions are pending.<\/p>\n Bottom line: Medicare beneficiaries with type 2 diabetes have had Ozempic and Mounjaro coverage since launch<\/p>\n Yes, but only for the cardiovascular indication. Medicare Part D plans began covering Wegovy in March 2024 for adults with overweight or obesity plus existing cardiovascular disease, based on SELECT trial data showing a 20% reduction in major adverse cardiovascular events. Coverage for weight loss alone is still statutorily prohibited.<\/p>\n It would require Congress to pass the Treat and Reduce Obesity Act or similar legislation, since the exclusion is statutory under 42 U.S.C. 1395w-102(e)(2). TROA has been introduced in every Congress since 2012 without passage. Some advocates argue CMS could reinterpret the exclusion through regulation, but courts have not ruled on that authority.<\/p>\n Yes, for moderate to severe obstructive sleep apnea in adults with obesity, based on the December 2024 FDA approval. The OSA indication is not “weight loss” under the Medicare exclusion. Coverage for obesity alone is not available through Medicare Part D.<\/p>\n A January 2024 KFF analysis found Medicare gross spending on Ozempic alone reached $5.7 billion in 2022, making it Medicare’s second-largest drug. Total Medicare GLP-1 spending including Trulicity, Mounjaro, and Wegovy likely exceeds $15 billion annually by 2025, with growth continuing as cardiovascular and OSA coverage expand.<\/p>\n The Treat and Reduce Obesity Act is proposed legislation that would explicitly authorize Medicare to cover anti-obesity medications and intensive behavioral therapy. It has bipartisan sponsorship but has not passed Congress since first being introduced in 2012, primarily because of CBO scoring concerns about long-term costs.<\/p>\n About 16 state Medicaid programs cover Wegovy or Zepbound for obesity as of 2026, with significant variation in prior authorization requirements. The remaining states cover GLP-1s only for diabetes or limited comorbidity-based indications. All state Medicaid programs cover the diabetes indications.<\/p>\n Yes. Medicare beneficiaries who don’t qualify for covered indications often choose to pay cash for either branded products through manufacturer direct programs or compounded semaglutide and tirzepatide through telehealth platforms. The two coverage pathways do not conflict. TrimRx and similar services operate on a cash-pay model that doesn’t bill Medicare.<\/p>\n Disclaimer:<\/strong> This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.<\/p>\n","protected":false},"excerpt":{"rendered":" Medicare’s relationship with GLP-1 drugs is the single most important coverage question in US healthcare policy.<\/p>\n","protected":false},"author":11,"featured_media":93130,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"Medicare and GLP-1: Will Government Programs Cover Weight Loss Drugs?","_yoast_wpseo_metadesc":"Medicare's relationship with GLP-1 drugs is the single most important coverage question in US healthcare policy.","_yoast_wpseo_focuskw":"medicare glp1 coverage","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[12],"tags":[23,29,30,56],"class_list":["post-90205","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-weight-loss","tag-cost-coverage","tag-glp-1","tag-insurance","tag-weight-loss"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90205","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=90205"}],"version-history":[{"count":1,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90205\/revisions"}],"predecessor-version":[{"id":91654,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90205\/revisions\/91654"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/93130"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=90205"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=90205"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=90205"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}How Did Wegovy Get Medicare Coverage?<\/h2>\n
How Did Zepbound Get Medicare Coverage?<\/h2>\n
Does Medicare Cover Ozempic\u00ae and Mounjaro\u00ae?<\/h2>\n
What About FLOW and Chronic Kidney Disease?<\/h2>\n
What Is the Treat and Reduce Obesity Act?<\/h2>\n
How Does Medicaid Handle GLP-1 Coverage?<\/h2>\n
What About the VA and Tricare?<\/h2>\n
What Does the Future Look Like for Medicare GLP-1 Coverage?<\/h2>\n
How Do Prices and Out-of-pocket Costs Work?<\/h2>\n
What Are Alternatives for Medicare Beneficiaries Without Coverage?<\/h2>\n
FAQ<\/h2>\n
Can Medicare Cover Wegovy in 2026?<\/h3>\n
Will Medicare Ever Cover GLP-1 for Weight Loss?<\/h3>\n
Does Medicare Cover Zepbound?<\/h3>\n
How Much Does Medicare Spend on GLP-1 Drugs?<\/h3>\n
What Is TROA?<\/h3>\n
Does Medicaid Cover Wegovy and Zepbound?<\/h3>\n
Can I Use Medicare and a Telehealth GLP-1 Program at the Same Time?<\/h3>\n